Common use of COSTS AND PAYMENT SCHEDULE Clause in Contracts

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-4 will be US$ [**] made up of: ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Manufacture and supply of two batches each of [**] kg Bulk Product US$ [**] - Process analysis (Section 2.2.2) US$ [**] - Development and validation of HPLC method (Section 2.2.3) US$ [**] - Evaluation of microscopy methods (Section 2.2.4) US$ [**] - Evaluation of other methods (Section 2.2.5) US$ [**] Payments will be made by Barrier to Abbott as follows: - US$ [**] within 30 days of signature of this Schedule B-4, and - US$ [**] Barrier's receipt of Abbott's report. ABBOTT GMBH & CO. KG BARRIER XXXXXXXXTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ----------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 24/04/03 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 24tx Xxxxx 0003 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-5 DEVELOPMENT AND PREPARATION OF REGISTRATION BATCHES (STAGES 5 AND 6) 1. AIM OF WORK As a result of the pilot biostudy carried out by Barrier using Bulk Product supplied by Abbott according to Schedule B-2, Barrier now wishes Abbott to perform the necessary additional pharmaceutical development programme and manufacture of six (6) batches each of [**] kg Bulk Product to be used for a pivotal study and for long-term stability testing prior to submission by Barrier of an NDA for Finished Product. The technical responsibilities are described hereunder.

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-4 B-2 will be US$ [**] ], made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Manufacture and supply of two batches each of [**] kg Bulk Product US$ Process analysis US $ [**] - Process analysis Short term stability study (Section 2.2.22.2.3) US$ US $ [**] - Development and validation (transferred from Section 2.2.2 of HPLC method (Section 2.2.3Schedule B-1) US$ [**] - Evaluation of microscopy methods (Section 2.2.4) US$ [**] - Evaluation of other methods (Section 2.2.5) US$ [**] Payments will be made to Abbott by Barrier to Abbott as follows: - US$ US $ [**] within 30 days of signature of this Schedule B-4B-2, and - US$ US $ [**] on Barrier's receipt of the first GMP batch of Bulk Product from Abbott, - US $ [**] on Barrier's receipt of the second GMP batch of Bulk Product from Abbott, - US $ [**] exclusivity milestone payment (in accordance with Schedule A) on Barrier's receipt of the second GMP batch of Bulk Product from Abbott, and - US $ [**] on Barrier's receipt of the short term stability report. ABBOTT GMBH & CO. KG BARRIER XXXXXXXXTICSTHERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ----------------------------------- ---------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 24/04/03 30 September 2002 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 24tx Xxxxx 0003 27 Xxxxxxxxx 2002 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-5 DEVELOPMENT AND PREPARATION OF REGISTRATION BATCHES (STAGES 5 AND 6)B-3 WORKPLAN FOR STAGE 3 1. AIM OF WORK As a result of the pilot biostudy carried out by Barrier using Bulk Product supplied by Abbott according to Schedule B-2, Barrier now wishes Abbott to perform the necessary additional pharmaceutical development programme and will manufacture of six (6) batches each of [**] kg Bulk Product Product, or the maximum amount that can be manufactured out of the remainder material, to be used for a pivotal study technical assessment and further manufacturing trials. The selected conditions are equivalent to the selected conditions for long-term stability testing prior to submission by Barrier of an NDA for Finished Productthe manufacture under SCHEDULE B-2. The technical responsibilities are will be described hereunderhereinafter.

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-4 B-2 will be US$ [**] ], made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Manufacture and supply of two batches each of [**] kg Bulk Product US$ Process analysis US $ [**] - Process analysis Short term stability study (Section 2.2.22.2.3) US$ US $ [**] - Development and validation (transferred from Section 2.2.2 of HPLC method (Section 2.2.3Schedule B-1) US$ Payments will be made to Abbott by Barrier as follows: - [**] - Evaluation of microscopy methods (Section 2.2.4) US$ [**] - Evaluation of other methods (Section 2.2.5) US$ [**] Payments will be made by Barrier to Abbott as follows: - US$ [**] within 30 days of signature of this Schedule B-4, and - US$ [**] Barrier's receipt of Abbott's report. ABBOTT GMBH & CO. KG BARRIER XXXXXXXXTICSTHERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ----------------------------------- ---------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 24/04/03 30 September 2002 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 24tx Xxxxx 0003 27 Xxxxxxxxx 2002 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-5 DEVELOPMENT AND PREPARATION OF REGISTRATION BATCHES (STAGES 5 AND 6)B-3 WORKPLAN FOR STAGE 3 1. AIM OF WORK As a result of the pilot biostudy carried out by Barrier using Bulk Product supplied by Abbott according to Schedule B-2, Barrier now wishes Abbott to perform the necessary additional pharmaceutical development programme and will manufacture of six (6) batches each of [**] kg Bulk Product Product, or the maximum amount thax xxx be manufactured out of the remainder material, to be used for a pivotal study technical assessment and further manufacturing trials. The selected conditions are equivalent to the selected conditions for long-term stability testing prior to submission by Barrier of an NDA for Finished Productthe manufacture under SCHEDULE B-2. The technical responsibilities are will be described hereunderhereinafter.

COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-4 will be US$ [**] made up of: ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Manufacture and supply of two batches each of [**] kg Bulk Product US$ [**] - Process analysis (Section 2.2.2) US$ [**] - Development and validation of HPLC method (Section 2.2.3) US$ [**] - Evaluation of microscopy methods (Section 2.2.4) US$ [**] - Evaluation of other methods (Section 2.2.5) US$ [**] Payments will be made by Barrier to Abbott as follows: - US$ [**] within 30 days of signature of this Schedule thxx Xxxedule B-4, and - US$ [**] Barrier's receipt of Abbott's report. ABBOTT GMBH & CO. KG BARRIER XXXXXXXXTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ----------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 24/04/03 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 24tx Xxxxx 0003 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-5 DEVELOPMENT AND PREPARATION OF REGISTRATION BATCHES (STAGES 5 AND 6) 1. AIM OF WORK As a result of the pilot biostudy carried out by Barrier using Bulk Product supplied by Abbott according to Schedule B-2, Barrier now wishes Abbott to perform the perfoxx xxx necessary additional pharmaceutical development programme developmenx xxxxramme and manufacture of six (6) batches each of [**] kg Bulk Product to be used for a pivotal study and for long-term stability testing prior to submission by Barrier of an NDA for Finished Product. The technical responsibilities are described hereunder.